|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Sales tax receivable | ||||||||||||||||||||
| Deposit for Irwin acquisition | ||||||||||||||||||||
| Prepaid expense and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Deposit for MusclePharm asset acquisition | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use asset | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Derivative asset | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expense | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Product returns | ||||||||||||||||||||
| Term loan – current portion | ||||||||||||||||||||
| Term Loans | ||||||||||||||||||||
| Total term loan – current portion | ||||||||||||||||||||
| Lease liability – current portion | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Revolving line of credit | ||||||||||||||||||||
| Term loan, net of current portion and unamortized deferred finance costs | ||||||||||||||||||||
| Term Loans | ||||||||||||||||||||
| Total term loan, net of current portion and unamortized deferred finance costs | ||||||||||||||||||||
| Long-term lease liability, net of current portion | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||||||||||||||
| Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.01 par value, 120,000 shares authorized; 9,391 issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| TOTAL STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
